



26 April 2023

New Product Upgrade to ViMove⁺

Key highlights

- dorsaVi has upgraded its flagship ViMove⁺ product by expanding its library of modules with the introduction of a new “Run module”
- Physical therapists can now complete more extensive assessments on patients leveraging dorsaVi’s proprietary technology and AI driven algorithms
- dorsaVi aims to target clinicians and physical therapists, increasing its annualised recurring revenue while expanding the product usefulness to its clinical client base
- The new module will be offered stand alone, or in concert with the AMI module, to increase dorsaVi’s addressable market and to diversify its product offering

Melbourne, Australia, 26 April 2023: dorsaVi (ASX:DVL) (dorsaVi or the Company) is pleased to provide an update in relation to its leading product, ViMove⁺ with the introduction of a new “Run module”. Upgrades to the product were made following feedback from customers and strategic partners, demonstrating the Company’s commitment towards continuous improvement and product development.

Dr Andrew Ronchi, dorsaVi’s Chief Executive Officer, commented:

“I am pleased to share we have upgraded our best-selling ViMove⁺ product by introducing our brand-new Run module. This upgrade allows clinicians to capture meaningful real-time data, which provides clinicians with insights that the human eye cannot capture. We listened to our customers and included a new offering that expands the product capability, allowing clinicians to improve their quality of care, and deliver better patient outcomes. We believe this has greatly enhanced the quality of our product as an all-purpose tool for physical therapy assessments, expanding our addressable market to new patient groups, and increasing our recurring revenue.”

dorsaVi’s Run module offers users a simple and effective method of assessing the physical performance of patients during the running motion. Running data is automatically analysed by dorsaVi’s AI based algorithms to deliver advanced insights into key running metrics and identify potential inefficiencies in a patient’s movement. These metrics are designed to help clinicians and patients leverage new performance insights, address biomechanical inefficiencies, monitor rehabilitation progression, and assess movement dysfunction all using objective data. Clinicians and physical therapists will now have greater autonomy to select their assessments of choice while providing real-time feedback and tailored corrective exercise programs for patients.

The Run module forms an important part of the ViMove⁺ product, as it expands the library of modules available to clinicians, while increasing the product usefulness and growing its addressable market. The upgrade further enhances the user experience, providing multiple modes of assessment from a single device, offering a superior value proposition for customers.

dorsaVi aims to generate greater recurring revenues from the new module and to drive further sales growth. The new module will be priced either individually or packaged with the Company's other modules, offering a diversified revenue stream. dorsaVi remains committed to refining its product portfolio based on feedback from its client base and is focused on improving patient outcomes.

This update has been authorised for lodgement to the ASX by the Company's Disclosure Committee.

– ENDS –

For further information about dorsaVi, please contact:

Company

Andrew Ronchi
Chief Executive Officer
+61 417 882 267
Email: ar@dorsavi.com

Investors

Dean Dribbin
Vesparum Capital
+61 3 8582 4800
Email: dorsavi@vesparum.com

About dorsaVi – Further information is available at www.dorsavi.com

dorsaVi Ltd (ASX: DVL) is an ASX listed company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove, ViMove2 and Professional Suite) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refers to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.